Provention Bio, a biopharmaceutical company based in Red Bank, recently announced the closing of a $35 million equity investment from Bridgewater-based Sanofi US. The deal is part of a previously ...

Provention Bio (NASDAQ:PRVB) says that a study of its PRV-031 drug found that it is effective at delaying patients from developing type 1 diabetes. The results from the study show that the treatment ...

Following Sanofi‘s $35 million equity investment last month, the global health care company will acquire Red Bank-based Provention Bio Inc. for $25 per share, representing an equity value of ...

Provention Bio Inc (NASDAQ:PRVB) shares are rocketing higher Monday after Sanofi (NASDAQ:SNY) announced plans to acquire the biopharmaceutical company. What Happened: Sanofi and Provention Bio entered ...

(Reuters) - Provention Bio said on Thursday the U.S. Food and Drug Administration had approved the use of its drug teplizumab in those aged eight years and older, the first treatment aimed at delaying ...

-If Approved Teplizumab will be the First Disease-Modifying Therapy for Type 1 Diabetes - Certain statements in this press release are forward-looking, including but not limited to, statements ...

Provention Bio Inc (NASDAQ:PRVB) shares are trading higher by 20.6% to $5.97 Thursday morning after the company announced it has entered into a co-promotion agreement with Sanofi U.S. for the launch ...

OLDWICK, N.J., June 15, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced extended ...

Tourlite Capital Management, an investment management company, released its fourth-quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, Tourlite Fund Founder ...

Provention Bio is rolling out its first disease awareness campaigns to drive early testing for Type 1 diabetes. (Getty Images) () Provention Bio wants to connect the familial threads around Type 1 ...

With a market cap of $391 million -- and a share price of $4.80 as of this writing -- Provention Bio is squarely within small-cap and penny stock territory. However, one could argue that the market is ...

RED BANK, N.J., April 8, 2021 /PRNewswire/ — Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the ...